Literature DB >> 68089

Immunologic studies in pneumococcal disease.

T H Dee, G Schiffman, M I Sottile, M W Rytel.   

Abstract

Many patients die from pneumococcal disease despite the availability of effective antimicrobial agents. Immunologic studies including detection, typing, and quantitation of serum pneumococcal capsular polysaccharide (PCP) antigen by counterimmunoelectrophoresis (CIE), quantitation of PCP antibody by radioimmunoassay (RIA), and quantitation of serum complement components C3, C4, and C3PA and serum immunoglobulins IgG, IgM, and IgA by the radial immunodiffusion technique of Mancini were performed with the sera of 18 patients. Five patients died (group I), and 13 survived (group II) pneumococcal infection. Both groups were comparable in age, underlying disease, and leukopenia on admission. All patients of group I and 10 of 13 (77%) of group II patients were bacteremic. Two patients in each group had an extrapulmonary focus infection. PCP antigen was detected in the sera of all group I and nine of 13 group II patients. PCP antigen levels were larger than or equal to 15 microng/ml in four of five group I and two of 13 group II patients (p = 0.022). Levels of antibody to PCP exceeded 100 ng/ml of antibody nitrogen (AbN) in 10 of 12 group II and one of five group I patients (p = 0.027) during the course of illness. All group I patients and three of 12 group II patients had decreased levels of one or more complement components on admission (p less than 0.01). One or more complement components remained decreased until death in four group I patients but returned to normal or elevated levels in all group II patients. No difference in serum immunoglobulin concentrations were found.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 68089

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  15 in total

1.  Pneumolysin-induced complement depletion during experimental pneumococcal bacteremia.

Authors:  R B Alcantara; L C Preheim; M J Gentry-Nielsen
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

2.  The effect of complement depletion on lung clearance of bacteria.

Authors:  G N Gross; S R Rehm; A K Pierce
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

3.  Abnormal antibody responses in patients with persistent generalized lymphadenopathy.

Authors:  H D Ochs; A K Junker; A C Collier; F S Virant; H H Handsfield; R J Wedgwood
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

4.  Pneumococcal intracellular killing is abolished by polysaccharide despite serum complement activity.

Authors:  J E Schweinle
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

5.  S. pneumoniae: important contributor to morbidity and mortality in patients with chronic obstructive pulmonary disease--fact or fiction?

Authors:  A L Davis; C P Aranda; L C Christianson
Journal:  Trans Am Clin Climatol Assoc       Date:  1987

6.  Determination of antibodies to pneumococcal C polysaccharide in patients with community-acquired pneumonia.

Authors:  H Holmberg; A Krook; A M Sjögren
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

7.  Alterations in serum opsonic activity and complement levels in pneumococcal disease.

Authors:  G S Giebink; T H Dee; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

8.  Pneumococcal antibody levels in patients with acute lung infiltrates.

Authors:  A Löwenberg; J A Snijder; L T vd Weele; H J Sluiter
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

9.  Isolation and characterization of circulating immune complexes from patients with pneumococcal pneumonia.

Authors:  M A Mellencamp; L C Preheim; T L McDonald
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

10.  Demonstration of circulating pneumococcal immunoglobulin G immune complexes in patients with community-acquired pneumonia by means of an enzyme-linked immunosorbent assay.

Authors:  Y Holloway; J A Snijder; W G Boersma
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.